We invest in :
– Clinical phase 2 of therapeutic drug development.
– Medical device and diagnostics, but only if the technology is a paradigm shift or if the equipment has a significant track record of success.
– Important unmet medical needs
– A clear and efficient regulatory path in capital
– Experienced leadership with a track record of success
– Solid and consolidated IP position
– Evidence of human efficacy or data in preferred patients
– Large addressable markets
– Diversified channeling with multiple “shots on goal ”
– Indications and disease areas of interest in partnerships with large pharmaceutical companies